Phase 3 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older.
- People who have heart failure caused by reduced blood flow to the heart (ischemic origin), with symptoms classified as moderate to severe (NYHA Class II to IV).
- People whose heart's pumping strength (left ventricular ejection fraction) was measured between 40–49% at the screening visit.
- People with a specific heart protein marker (NT-proBNP) level of 125 pg/ml or higher in their blood.
- People who have signs of structural or functional changes to the left side of the heart.
- People who are already taking the recommended heart failure medications (a type of blood pressure tablet called an ACEI or ARB, and a beta-blocker), unless those medications are not suitable for them.
- People who have provided written agreement to take part before any study procedures begin.
Who may not be able to join:
- People with a known allergy or bad reaction to any of the study drugs, or to medications in the same drug families (ACEIs, ARBs, or neprilysin inhibitors).
- People who have previously been unable to tolerate the recommended doses of ACEI or ARB medications.
- People with a known history of a condition called angioedema (a type of serious swelling reaction).
- People who need to take both an ACEI and an ARB medication at the same time.
- People who had a sudden worsening of heart failure in the 6 weeks before the screening visit.
- People whose blood pressure was too low (systolic below 100 mmHg) at the screening visit.
- People who are currently taking, or have previously taken, a medication called sacubitril/valsartan.
- People whose kidneys are not working well enough, based on a specific measurement taken at the screening visit (confirm with trial site).
- People with potassium levels in their blood that are too high (above 5.2 mmol/L) at the screening visit.
- People who had a heart attack or a planned procedure to open blocked heart arteries within the 6 weeks before screening.
- People who had a stroke, a mini-stroke (TIA), a neck artery procedure, heart surgery, or other major heart-related surgery within the 3 months before screening.
- People who have a pacemaker, defibrillator, or heart resynchronisation device that is not compatible with MRI scans.
- People with a permanent (fixed) form of an irregular heart rhythm called atrial fibrillation.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +48 12 6142218
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in left ventricular end-systolic volume
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.